Jaguar Health Faces Potential Delisting from NASDAQ

TL;DR

**Jaguar Health is in hot water with NASDAQ, facing a potential delisting!**

AI Summary

Jaguar Health, Inc. (NASDAQ: JAGX) filed an 8-K on February 15, 2024, regarding a notice of delisting or failure to satisfy a continued listing rule or standard, and a transfer of listing. The company, incorporated in Delaware with business operations in San Francisco, CA, has a Commission File Number 001-36714 and an IRS Employer Identification No. 46-2956775. This filing indicates potential issues with its NASDAQ listing status.

Why It Matters

This filing signals that Jaguar Health, Inc. is at risk of losing its listing on a major stock exchange, which could severely impact its ability to raise capital and its stock's liquidity.

Risk Assessment

Risk Level: high — A delisting notice indicates significant non-compliance with exchange rules, posing a severe threat to the company's public trading status and investor confidence.

Key Numbers

• 001-36714 — Commission File Number (SEC identification for Jaguar Health, Inc.)
• 46-2956775 — IRS Employer Identification No. (Tax identification for Jaguar Health, Inc.)
• 415-371-8300 — Business Phone Number (Contact number for Jaguar Health, Inc.)

Key Players & Entities

• Jaguar Health, Inc. (company) — Registrant facing delisting notice
• NASDAQ (company) — Stock exchange from which the company may be delisted
• February 15, 2024 (date) — Date of earliest event reported
• Delaware (company) — State of incorporation for Jaguar Health, Inc.
• San Francisco, California (company) — Location of principal executive offices for Jaguar Health, Inc.

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, Par Value $0.0001 Per Share JAGX The Nasdaq Capital Mar
• $1.00 — iness days had closed below the minimum $1.00 per share required for continued listin
• $0.10 — common stock had a closing bid price of $0.10 or less for 10 consecutive trading days

Filing Documents

• tm246476d1_8k.htm (8-K) — 28KB
• 0001104659-24-024908.txt ( ) — 198KB
• jagx-20240215.xsd (EX-101.SCH) — 3KB
• jagx-20240215_lab.xml (EX-101.LAB) — 33KB
• jagx-20240215_pre.xml (EX-101.PRE) — 22KB
• tm246476d1_8k_htm.xml (XML) — 4KB

01. Notice of Delisting or Failure to Satisfy a Continued

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on May 10, 2023, Jaguar Health, Inc. (the "Company") received a notification letter from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the bid price for the Company's common stock for the last 30 consecutive business days had closed below the minimum $1.00 per share required for continued listing under Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"). Under Nasdaq Listing Rule 5810(c)(3)(A), the Company was granted a 180 calendar day grace period, or until November 6, 2023, to regain compliance with the Minimum Bid Price Requirement. However, on November 8, 2023, the Staff notified the Company that it was eligible for an additional 180 calendar day period or until May 6, 2024, to regain compliance. On February 15, 2024, the Company received a letter from the Staff notifying the Company that as of February 14, 2024, the Company's common stock had a closing bid price of $0.10 or less for 10 consecutive trading days. Accordingly, the Company is subject to the provisions contemplated under Nasdaq Listing Rule 5810(c)(3)(A)(iii) (the "Low Priced Stocks Rule"). As a result, the Staff has issued a letter notifying the Company of its determination to delist the Company's securities from Nasdaq effective as of the opening of business on February 26, 2024, unless the Company requests an appeal before the Nasdaq Hearings Panel (the "Panel") of the Staff's determination on or prior to February 22, 2024, pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series. A hearing request will stay the suspension of the Company's securities and the filing of the Form 25-NSE pending the Panel's final decision following the hearing and any extension period that may be granted by the Panel. The Company's common stock will continue to trade on Nasdaq under th

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. JAGUAR HEALTH, INC. By: /s/ Lisa A. Conte Name: Lisa A. Conte Title: President and Chief Executive Officer Date: February 16, 2024

View Full Filing

View this 8-K filing on SEC EDGAR